List of Rezlidhia drug patents

Rezlidhia is owned by Rigel Pharms Inc.

Rezlidhia contains Olutasidenib.

Rezlidhia has a total of 10 drug patents out of which 0 drug patents have expired.

Rezlidhia was authorised for market use on 01 December, 2022.

Rezlidhia is available in capsule;oral dosage forms.

Rezlidhia can be used as a method of treating a cancer where the cancer is acute myeloid leukemia (aml), a method of treating a cancer characterized by an idh1 mutation where the cancer is acute myeloid leukemia (aml), a method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation.

Drug patent challenges can be filed against Rezlidhia from 2026-12-01.

The generics of Rezlidhia are possible to be released after 16 May, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9834539 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(12 years from now)

US10532047 RIGEL PHARMS INC Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
May, 2039

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11498913 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(12 years from now)

US10414752 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(12 years from now)

US10550098 RIGEL PHARMS INC Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(12 years from now)

US11376246 RIGEL PHARMS INC Inhibiting mutant IDH-1
May, 2039

(15 years from now)

US10959994 RIGEL PHARMS INC Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
May, 2039

(15 years from now)

US11013734 RIGEL PHARMS INC Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
May, 2039

(15 years from now)

US11497743 RIGEL PHARMS INC Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
May, 2039

(15 years from now)

US11013733 RIGEL PHARMS INC Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
May, 2039

(15 years from now)

Do you want to check out REZLIDHIA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 1, 2027
Orphan Drug Exclusivity (ODE) Dec 1, 2029

Drugs and Companies using OLUTASIDENIB ingredient

NCE-1 date: 2026-12-01

Market Authorisation Date: 01 December, 2022

Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is ac...

Dosage: CAPSULE;ORAL

More Information on Dosage

REZLIDHIA family patents

56

United States

6

European Union

5

Australia

4

Spain

4

Morocco

4

Mexico

3

Canada

3

Japan

3

Israel

2

Denmark

2

RS

2

Poland

2

China

EA

2

EA

2

Croatia

2

Portugal

2

Lithuania

2

Slovenia

1

Philippines

1

Malaysia

1

Brazil

1

Singapore

1

Argentina

1

ME

1

New Zealand

1

Korea, Republic of

1

Cyprus

1

Peru

1

Chile

1

Taiwan

1

Ecuador

1

South Africa

1

Colombia

1

Saudi Arabia

1

Hungary

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in